Octreotide for the Management of Neuroendocrine Tumours

A clinical practice guideline for the management of neuroendocrine tumours of the gastrointestinal tract, pancreas, lungs, thyroid, parathyroid, adrenal glands, and pituitary gland, and of unknown origin. The guideline examines symptom management and dosing regimens for treatment with octreotide. Outcomes of interest include slowed tumour progression and improved prophylactic use.